Pten

Annual Review of Biochemistry

Volumn 83, Issue , 2014, Pages 641-669

  Worby, Carolyn A ^a   Dixon, Jack E ^a  

^a San Diego   (United States)

Author keywords

cancer; phosphatase; tumor suppressor

Indexed keywords

LONG UNTRANSLATED RNA; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; LIPID; OXYGEN; PTEN PROTEIN, HUMAN; UBIQUITIN;

ACETYLATION; CELL CYCLE PROGRESSION; CELL GROWTH; CELL METABOLISM; CELL MIGRATION; CELL POLARITY; CELL RENEWAL; CELLULAR DISTRIBUTION; CYTOARCHITECTURE; ENZYME ACTIVITY; ENZYME SPECIFICITY; EPIGENETICS; GENE LOCUS; HUMAN; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; STEM CELL; SUMOYLATION; TRANSCRIPTION REGULATION; UBIQUITINATION; ANIMAL; CELL CYCLE; CELL MOTION; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN MULTIMERIZATION; PROTEIN TERTIARY STRUCTURE;

ANIMALS; CELL CYCLE; CELL MOVEMENT; CELL NUCLEUS; CELL POLARITY; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIPIDS; NEOPLASMS; OXYGEN; PHOSPHORYLATION; PROGNOSIS; PROTEIN INTERACTION MAPPING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; PTEN PHOSPHOHYDROLASE; SUBSTRATE SPECIFICITY; UBIQUITIN;

EID: 84902129859     PISSN: 00664154     EISSN: 15454509     Source Type: Book Series    
DOI: 10.1146/annurev-biochem-082411-113907     Document Type: Review

References (207)

1. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-47
2. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, et al. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:356-62
3. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, et al. 1997. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16:64-67
4. Parsons R. 1998. Phosphatases and tumorigenesis. Curr. Opin. Oncol. 10:88-91
5. Cairns P, Evron E, Okami K, Halachmi N, Esteller M, et al. 1998. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 16:3215-18
6. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, et al. 1998. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16:2259-64
7. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, et al. 1998. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8:1169-78
8. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. 1998. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19:348-55
9. Zhang XC, Piccini A, Myers MP, Van Aelst L, Tonks NK. 2012. Functional analysis of the protein phosphatase activity of PTEN. Biochem. J. 444:457-64
10. Li DM, Sun H. 1997. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor ?. Cancer Res. 57:2124-29
11. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. 1998. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280:1614-17
12. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, et al. 1997. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc. Natl. Acad. Sci. USA 94:9052-57
13. Maehama T, Dixon JE. 1998. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273:13375-78
14. Maehama T,Dixon JE. 1999. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 9:125-28
15. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, et al. 1998. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. USA 95:13513-18
16. Kaplan DR,Whitman M, Schaffhausen B, Pallas DC,White M, et al. 1987. Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell 50:1021-29
17. Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM. 1985. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 315:239-42
18. Engelman JA, Luo J, Cantley LC. 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7:606-19
19. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. 2010. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11:329-41
20. Zhang TT, Li H, Cheung SM, Costantini JL, Hou S, et al. 2009. Phosphoinositide 3-kinase-regulated adapters in lymphocyte activation. Immunol. Rev. 232:255-72
21. Hunzicker-DunnME, Lopez-Biladeau B, Law NC, Fiedler SE, Carr DW, Maizels ET. 2012. PKA and GAB2 play central roles in the FSH signaling pathway to PI3K and AKT in ovarian granulosa cells. Proc. Natl. Acad. Sci. USA 109:E2979-88
22. Salamon RS, Backer JM. 2013. Phosphatidylinositol-3,4,5-trisphosphate: tool of choice for class I PI 3-kinases. BioEssays 35:602-11
23. Cantley LC. 2002. The phosphoinositide 3-kinase pathway. Science 296:1655-57
24. Stephens L, Hawkins P. 2011. Signalling via class IA PI3Ks. Adv. Enzyme Regul. 51:27-36
25. Brazil DP, Park J, Hemmings BA. 2002. PKB binding proteins. Getting in on the Akt. Cell 111:293-303
26. Manning BD, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell 129:1261-74
27. Guertin DA, Sabatini DM. 2007. Defining the role of mTOR in cancer. Cancer Cell 12:9-22
28. Downward J. 1998. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10:262-67
29. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, et al. 1998. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29-39
30. Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, et al. 1998. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res. 58:5667-72
31. Blero D, Payrastre B, Schurmans S, Erneux C. 2007. Phosphoinositide phosphatases in a network of signalling reactions. Pflüg. Arch. 455:31-44
32. Di Paolo G, De Camilli P. 2006. Phosphoinositides in cell regulation and membrane dynamics. Nature 443:651-57
33. Maffucci T. 2012. An introduction to phosphoinositides. Curr. Top. Microbiol. Immunol. 362:1-42
34. Lo SH, Weisberg E, Chen LB. 1994. Tensin: a potential link between the cytoskeleton and signal transduction. BioEssays 16:817-23
35. Zhao X, Greener T, Al-Hasani H, Cushman SW, Eisenberg E, Greene LE. 2001. Expression of auxilin or AP180 inhibits endocytosis bymislocalizing clathrin: evidence for formation of nascent pits containing AP1 or AP2 but not clathrin. J. Cell Sci. 114:353-65
36. Yuvaniyama J, Denu JM, Dixon JE, Saper MA. 1996. Crystal structure of the dual specificity protein phosphatase VHR. Science 272:1328-31
37. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, et al. 1999. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99:323-34
38. 2+-binding domain. J. Biol. Chem. 273:15879-82
39. Guipponi M, Yaspo ML, Riesselman L, Chen H, De Sario A, et al. 2000. Genomic structure of a copy of the human TPTE gene which encompasses 87 kb on the short arm of chromosome 21. Hum. Genet. 107:127-31
40. Tapparel C, Reymond A, Girardet C, Guillou L, Lyle R, et al. 2003. The TPTE gene family: cellular expression, subcellular localization and alternative splicing. Gene 323:189-99
41. Chen H, Rossier C, Morris MA, Scott HS, Gos A, et al. 1999. A testis-specific gene, TPTE, encodes a putative transmembrane tyrosine phosphatase and maps to the pericentromeric region of human chromosomes 21 and 13, and to chromosomes 15, 22, and Y. Hum. Genet. 105:399-409
42. Walker SM, Downes CP, Leslie NR. 2001. TPIP: a novel phosphoinositide 3-phosphatase. Biochem. J. 360:277-83
43. Mishra RR, Chaudhary JK, Bajaj GD, Rath PC. 2011. A novel human TPIP splice-variant (TPIP-C2) mRNA, expressed in human and mouse tissues, strongly inhibits cell growth in HeLa cells. PLoS ONE 6:e28433
44. Mishra RR, Chaudhary JK, Rath PC. 2012. Cell cycle arrest and apoptosis by expression of a novel TPIP (TPIP-C2) cDNA encoding a C2-domain in HEK-293 cells. Mol. Biol. Rep. 39:7389-402
45. Murata Y, Iwasaki H, Sasaki M, Inaba K, Okamura Y. 2005. Phosphoinositide phosphatase activity coupled to an intrinsic voltage sensor. Nature 435:1239-43
46. Murata Y, Okamura Y. 2007. Depolarization activates the phosphoinositide phosphatase Ci-VSP, as detected in Xenopus oocytes coexpressing sensors of PIP2. J. Physiol. 583:875-89
47. Iwasaki H, Murata Y, Kim Y, Hossain MI, Worby CA, et al. 2008. A voltage-sensing phosphatase, Ci-VSP, which shares sequence identity with PTEN, dephosphorylates phosphatidylinositol 4,5-bisphosphate. Proc. Natl. Acad. Sci. USA 105:7970-75
48. Okamura Y, Dixon JE. 2011. Voltage-sensing phosphatase: its molecular relationship with PTEN. Physiology 26:6-13
49. Arai Y, Shibata T, Matsuoka S, Sato MJ, Yanagida T, Ueda M. 2010. Self-organization of the phosphatidylinositol lipids signaling system for random cell migration. Proc. Natl. Acad. Sci. USA 107:12399-404
50. Funamoto S, Meili R, Lee S, Parry L, Firtel RA. 2002. Spatial and temporal regulation of 3-phosphoinositides by PI 3-kinase and PTEN mediates chemotaxis. Cell 109:611-23
51. Tang M, Iijima M, Kamimura Y, Chen L, Long Y, Devreotes P. 2011. Disruption of PKB signaling restores polarity to cells lacking tumor suppressor PTEN. Mol. Biol. Cell 22:437-47
52. Wessels D, Lusche DF, Kuhl S, Heid P, Soll DR. 2007. PTEN plays a role in the suppression of lateral pseudopod formation during Dictyostelium motility and chemotaxis. J. Cell Sci. 120:2517-31
53. Xu J, Wang F, Van Keymeulen A,Herzmark P, Straight A, et al. 2003. Divergent signals and cytoskeletal assemblies regulate self-organizing polarity in neutrophils. Cell 114:201-14
54. Damen JE, Liu L, Rosten P, Humphries RK, Jefferson AB, et al. 1996. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase. Proc. Natl. Acad. Sci. USA 93:1689-93
55. Mondal S, Subramanian KK, Sakai J, Bajrami B, Luo HR. 2012. Phosphoinositide lipid phosphatase SHIP1 and PTEN coordinate to regulate cell migration and adhesion. Mol. Biol. Cell 23:1219-30
56. Heit B, Robbins SM, Downey CM, Guan Z, Colarusso P, et al. 2008. PTEN functions to "prioritize" chemotactic cues and prevent "distraction" in migrating neutrophils. Nat. Immunol. 9:743-52
57. Li Y, Jia Y, Pichavant M, Loison F, Sarraj B, et al. 2009. Targeted deletion of tumor suppressor PTEN augments neutrophil function and enhances host defense in neutropenia-Associated pneumonia. Blood 113:4930-41
58. Schabbauer G, Matt U, Günzl P, Warszawska J, Furtner T, et al. 2010. Myeloid PTEN promotes inflammation but impairs bactericidal activities during murine pneumococcal pneumonia. J. Immunol. 185:468-76
59. Subramanian KK, Jia Y, Zhu D, Simms BT, Jo H, et al. 2007. Tumor suppressor PTEN is a physiologic suppressor of chemoattractant-mediated neutrophil functions. Blood 109:4028-37
60. Lubarsky B, KrasnowMA. 2003. Tube morphogenesis: making and shaping biological tubes. Cell 112:19-28
61. Gassama-Diagne A, Yu W, ter BeestM,Martin-Belmonte F, Kierbel A, et al. 2006. Phosphatidylinositol-3,4,5-trisphosphate regulates the formation of the basolateral plasma membrane in epithelial cells. Nat. Cell Biol. 8:963-70
62. Martin-Belmonte F, Gassama A, Datta A, Yu W, Rescher U, et al. 2007. PTEN-mediated apical segregation of phosphoinositides controls epithelial morphogenesis through Cdc42. Cell 128:383-97
63. Song LB, Li J, Liao WT, Feng Y, Yu CP, et al. 2009. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J. Clin. Investig. 119:3626-36
64. Ogg S, Ruvkun G. 1998. The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol. Cell 2:887-93
65. Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. 1993. A C. elegans mutant that lives twice as long as wild type. Nature 366:461-64
66. Goberdhan DC, Paricio N, Goodman EC, Mlodzik M, Wilson C. 1999. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev. 13:3244-58
67. Gao X, Neufeld TP, Pan D. 2000. Drosophila PTEN regulates cell growth and proliferation through PI3K-dependent and -independent pathways. Dev. Biol. 221:404-18
68. Scanga SE, Ruel L, Binari RC, Snow B, Stambolic V, et al. 2000. The conserved PI3-K/PTEN/Akt signaling pathway regulates both cell size and survival in Drosophila. Oncogene 19:3971-77
69. Cohen P, Frame S. 2001. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2:769-76
70. Berwick DC, Hers I, Heesom KJ, Moule SK, Tavare JM. 2002. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J. Biol. Chem. 277:33895-900
71. Cong LN, Chen H, Li Y, Zhou L, McGibbon MA, et al. 1997. Physiological role of Akt in insulinstimulated translocation of GLUT4 in transfected rat adipose cells. Mol. Endocrinol. 11:1881-90
72. Kohn AD, Summers SA, BirnbaumMJ, Roth RA. 1996. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J. Biol. Chem. 271:31372-78
73. Barthel A, Schmoll D, Unterman TG. 2005. FoxO proteins in insulin action and metabolism. Trends Endocrinol. Metab. 16:183-89
74. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, et al. 2004. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Investig. 113:1774-83
75. Stiles B,Wang Y, Stahl A, Bassilian S, Lee WP, et al. 2004. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc. Natl. Acad. Sci. USA 101:2082-87
76. Knobbe CB, Lapin V, Suzuki A, Mak TW. 2008. The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey. Oncogene 27:5398-415
77. Garcia-Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, et al. 2012. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 149:49-62
78. Ortega-Molina A, Efeyan A, Lopez-Guadamillas E, Munoz-Martin M, G?mez-Löpez G, et al. 2012. Pten positively regulates brown adipose function, energy expenditure, and longevity. CellMetab. 15:382-94
79. Hsu PP, Sabatini DM. 2008. Cancer cell metabolism: Warburg and beyond. Cell 134:703-07
80. Israelsen WJ, VanderHeidenMG. 2010. ATP consumption promotes cancermetabolism. Cell 143:669-71
81. Warburg O. 1956. On respiratory impairment in cancer cells. Science 124:269-70
82. Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH. 1997. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J. Biol. Chem. 272:17269-75
83. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. 2001. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 15:1406-18
84. Bertout JA, Patel SA, SimonMC. 2008. The impact ofO2 availability on human cancer. Nat. Rev. Cancer 8:967-75
85. Majmundar AJ, Wong WJ, Simon MC. 2010. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40:294-309
86. Semenza GL. 2012. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33:207-14
87. Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, et al. 2010. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39:171-83
88. Sears RC, Nevins JR. 2002. Signaling networks that link cell proliferation and cell fate. J. Biol. Chem. 277:11617-20
89. Tran H, Brunet A, Griffith EC, Greenberg ME. 2003. The many forks in FOXO's road. Sci. Signal Transduct. Knowl. Environ. 4:RE5
90. Vivanco I, Sawyers CL. 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2:489-501
91. Massague J. 2004. G1 cell-cycle control and cancer. Nature 432:298-306
92. Warr MR, Pietras EM, Passegu? E. 2011. Mechanisms controlling hematopoietic stem cell functions during normal hematopoiesis and hematological malignancies. Wiley Interdiscip. Rev. Syst. Biol. Med. 3:681-701
93. Pietras EM, Warr MR, Passegu? E. 2011. Cell cycle regulation in hematopoietic stem cells. J. Cell Biol. 195:709-20
94. Yilmaz OH, Valdez R, Theisen BK, GuoW, Ferguson DO, et al. 2006. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441:475-82
95. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, et al. 2006. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441:518-22
96. Magee JA, Ikenoue T, Nakada D, Lee JY, Guan KL, Morrison SJ. 2012. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 11:415-28
97. Hanahan D,Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-74
98. Kalluri R, Zeisberg M. 2006. Fibroblasts in cancer. Nat. Rev. Cancer 6:392-401
99. Trimboli AJ, Cantemir-Stone CZ, Li F,Wallace JA, Merchant A, et al. 2009. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461:1084-91
100. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, et al. 2012. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat. Cell Biol. 14:159-67
101. Gibson GE, Huang HM. 2002. Oxidative processes in the brain and non-neuronal tissues as biomarkers of Alzheimer's disease. Front. Biosci. 7:D1007-15
102. Pap T, Franz JK, Hummel KM, Jeisy E, Gay R, Gay S. 2000. Activation of synovial fibroblasts in rheumatoid arthritis: lack of expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res. 2:59-64
103. White ES, Atrasz RG, Hu B, Phan SH, Stambolic V, et al. 2006. Negative regulation of myofibroblast differentiation by PTEN (phosphatase and tensin homolog deleted on chromosome 10). Am. J. Respir. Crit. Care Med. 173:112-21
104. Hopkins BD, Fine B, Steinbach N, Dendy M, Rapp Z, et al. 2013. A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science 341:399-402
105. Subramanian T, Govindarajan R, Chinnadurai G. 1991. Heterologous basic domain substitutions in the HIV-1 Tat protein reveal an arginine-rich motif required for transactivation. EMBO J. 10:2311-18
106. Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward NK, Eng C. 2002. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int. J. Cancer 99:63-67
107. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, et al. 2000. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am. J. Pathol. 156:1693-700
108. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, et al. 1999. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. 155:1253-60
109. Ginn-Pease ME, Eng C. 2003. Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 cells. Cancer Res. 63:282-86
110. Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H. 2008. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol. Cell. Biol. 28:3281-89
111. Song MS, Carracedo A, Salmena L, Song SJ, Egia A, et al. 2011. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase- independent manner. Cell 144:187-99
112. Manchado E, Eguren M, MalumbresM. 2010. The anaphase-promoting complex/cyclosome (APC/C): cell-cycle-dependent and -independent functions. Biochem. Soc. Trans. 38:65-71
113. Wäsch R, Robbins JA, Cross FR. 2010. The emerging role of APC/CCdh1 in controlling differentiation, genomic stability and tumor suppression. Oncogene 29:1-10
114. ShenWH, Balajee AS,Wang J,WuH,Eng C, et al. 2007. Essential role for nuclearPTENinmaintaining chromosomal integrity. Cell 128:157-70
115. Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, et al. 2009. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 8:2198-210
116. Ming M, He YY. 2012. PTEN in DNA damage repair. Cancer Lett. 319:125-29
117. Planchon SM,Waite KA, Eng C. 2008. The nuclear affairs of PTEN. J. Cell Sci. 121:249-53
118. Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T. 2005. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3?. J. Biol. Chem. 280:35195-202
119. Maccario H, Perera NM, Davidson L, Downes CP, Leslie NR. 2007. PTEN is destabilized by phosphorylation on Thr366. Biochem. J. 405:439-44
120. Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA. 2013. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol. Cell. Biol. 33:3091-98
121. Miller SJ, Lou DY, SeldinDC,LaneWS, Neel BG. 2002. Direct identification ofPTENphosphorylation sites. FEBS Lett. 528:145-53
122. Birle D, Bottini N, Williams S, Huynh H, deBelle I, et al. 2002. Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation. J. Immunol. 169:286-91
123. + channels. J. Biol. Chem. 284:9331-40
124. Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK. 2005. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc. Natl. Acad. Sci. USA 102:2703-6
125. Li Z, Dong X, Wang Z, LiuW, Deng N, et al. 2005. Regulation of PTEN by Rho small GTPases. Nat. Cell Biol. 7:399-404
126. Bassi C, Ho J, Srikumar T, Dowling RJ, Gorrini C, et al. 2013. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 341:395-99
127. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, et al. 2007. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128:129-39
128. Yim EK, Peng G, Dai H, Hu R, Li K, et al. 2009. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15:304-14
129. Fouladkou F, Landry T, Kawabe H, Neeb A, Lu C, et al. 2008. The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc. Natl. Acad. Sci. USA 105:8585-90
130. Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, et al. 2010. Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am. J. Pathol. 177:2622-34
131. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, et al. 2007. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128:141-56
132. Maddika S, Kavela S, Rani N, Palicharla VR, Pokorny JL, et al. 2011. WWP2 is an E3 ubiquitin ligase for PTEN. Nat. Cell Biol. 13:728-33
133. Dai Y, Qiao L, Chan KW, YangM, Ye J, et al. 2009. Adenovirus-mediated down-regulation of X-linked inhibitor of apoptosis protein inhibits colon cancer. Mol. Cancer Ther. 8:2762-70
134. Jiang C, Yi XP, Shen H, Li YX. 2012. Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion. World J. Gastroenterol. 18:2956-65
135. Zhang S,Ding F, Luo A, Chen A, Yu Z, et al. 2007. XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol. Ther. 6:973-80
136. Van Themsche C, Leblanc V, Parent S, Asselin E. 2009. X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization. J. Biol. Chem. 284:20462-66
137. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, et al. 2008. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 455:813-17
138. Fridberg M, Servin A, Anagnostaki L, Linderoth J, Berglund M, et al. 2007. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-?II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk. Lymphoma 48:2221-32
139. Mazza M, Pelicci PG. 2013. Is PML a tumor suppressor? Front. Oncol. 3:174
140. Seo JH, Ahn Y, Lee SR, Yeo CY, Hur KC. 2005. The major target of the endogenously generated reactive oxygen species in response to insulin stimulation is phosphatase and tensin homolog and not phosphoinositide-3 kinase (PI-3 kinase) in the PI-3 kinase/Akt pathway. Mol. Biol. Cell 16:348-57
141. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, et al. 2004. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc. Natl. Acad. Sci. USA 101:16419-24
142. Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, et al. 2009. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J. 28:1505-17
143. Kim YC, Kitaura H, Taira T, Iguchi-Ariga SM, Ariga H. 2009. Oxidation of DJ-1-dependent cell transformation through direct binding of DJ-1 to PTEN. Int. J. Oncol. 35:1331-41
144. Okumura K,MendozaM, Bachoo RM,DePinho RA, Cavenee WK, Furnari FB. 2006. PCAF modulates PTEN activity. J. Biol. Chem. 281:26562-68
145. Ikenoue T, Inoki K, Zhao B, Guan KL. 2008. PTEN acetylation modulates its interaction with PDZ domain. Cancer Res. 68:6908-12
146. Qu Y, Zhang J,Wu S, Li B, Liu S, Cheng J. 2012. SIRT1 promotes proliferation and inhibits apoptosis of human malignant glioma cell lines. Neurosci. Lett. 525:168-72
147. Huang J, Yan J, Zhang J, Zhu S, Wang Y, et al. 2012. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat. Commun. 3:911
148. González-Santamar J, Campagna M, Ortega-Molina A,Marcos-Villar L, de la Cruz-Herrera CF, et al. 2012. Regulation of the tumor suppressor PTEN by SUMO. Cell Death Dis. 3:e393
149. Takahashi Y, Morales FC, Kreimann EL, Georgescu MM. 2006. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J. 25:910-20
150. Molina JR, AgarwalNK, Morales FC, Hayashi Y, AldapeKD, et al. 2012. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene 31:1264-74
151. O'Neill AK, Niederst MJ, Newton AC. 2013. Suppression of survival signalling pathways by the phosphatase PHLPP. FEBS J. 280:572-83
152. Kallakury BV, Sheehan CE, Ross JS. 2001. Co-downregulation of cell adhesion proteins ?-and ?-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum. Pathol. 32:849-55
153. Ruoslahti E, Obrink B. 1996. Common principles in cell adhesion. Exp. Cell Res. 227:1-11
154. Subauste MC, Nalbant P, Adamson ED, Hahn KM. 2005. Vinculin controls PTEN protein level by maintaining the interaction of the adherens junction protein ?-catenin with the scaffolding protein MAGI-2. J. Biol. Chem. 280:5676-81
155. Kotelevets L, van Hengel J, Bruyneel E, Mareel M, van Roy F, Chastre E. 2005. Implication of the MAGI-1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness. FASEB J. 19:115-17
156. Kotelevets L, van Hengel J, Bruyneel E, Mareel M, van Roy F, Chastre E. 2001. The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. J. Cell Biol. 155:1129-35
157. Adey NB, Huang L, Ormonde PA, Baumgard ML, Pero R, et al. 2000. Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res. 60:35-37
158. Cotter L, Ozçlik M, Jacob C, Pereira JA, Locher V, et al. 2010. Dlg1-PTEN interaction regulates myelin thickness to prevent damaging peripheral nerve overmyelination. Science 328:1415-18
159. EnomotoM, Igaki T. 2011. Deciphering tumor-suppressor signaling in flies: genetic link between Scribble/ Dlg/Lgl and the Hippo pathways. J. Genet. Genomics 38:461-70
160. Woods DF, Bryant PJ. 1989. Molecular cloning of the lethal(1)discs large-1 oncogene of Drosophila. Dev. Biol. 134:222-35
161. Bissell MJ, Radisky D. 2001. Putting tumours in context. Nat. Rev. Cancer 1:46-54
162. Valiente M, Andr?s-Pons A, Gomar B, Torres J, Gil A, et al. 2005. Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-Associated serine/threonine kinases. J. Biol. Chem. 280:28936-43
163. Terrien E, Chaffotte A, Lafage M, Khan Z, PrehaudC, et al. 2012. Interference with the PTEN-MAST2 interaction by a viral protein leads to cellular relocalization of PTEN. Sci. Signal. 5:ra58
164. Kreis P, van Diepen MT, Eickholt BJ. 2010. Regulation of PTEN in neurons by myosin-based transport mechanisms. Adv. Enzyme Regul. 50:119-24
165. Leslie NR, Spinelli L, Tibarewal P, Zilidis G, Weerasinghe N, et al. 2010. Indirect mechanisms of carcinogenesis via downregulation of PTEN function. Adv. Enzyme Regul. 50:112-18
166. van Diepen MT, Parsons M, Downes CP, Leslie NR, Hindges R, Eickholt BJ. 2009. MyosinV controls PTEN function and neuronal cell size. Nat. Cell Biol. 11:1191-96
167. Zhou J, Parada LF. 2009. A motor driving PTEN. Nat. Cell Biol. 11:1177-79
168. Chagpar RB, Links PH, Pastor MC, Furber LA, Hawrysh AD, et al. 2010. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. USA 107:5471-76
169. Fine B, Hodakoski C, Koujak S, Su T, Saal LH, et al. 2009. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science 325:1261-65
170. He L, Fan C, Kapoor A, Ingram AJ, Rybak AP, et al. 2011. Mannosidase 2C1 attenuates PTEN function in prostate cancer cells. Nat. Commun. 2:307
171. He L, Ingram A, Rybak AP, Tang D. 2010. Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. J. Clin. Investig. 120:2094-108
172. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, et al. 2001. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat. Cell Biol. 3:1124-28
173. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, et al. 2003. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 3:117-30
174. Shen YH, Zhang L, Gan Y, Wang X, Wang J, et al. 2006. Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling. A cross-talk between stress signaling and insulin signaling in resistin-treated human endothelial cells. J. Biol. Chem. 281:7727-36
175. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. 2001. Tumor suppressor and antiinflammatory actions of PPARγagonists are mediated via upregulation of PTEN. Curr. Biol. 11:764-68
176. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, et al. 2011. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 117:3617-28
177. Guo BH, Feng Y, Zhang R, Xu LH, Li MZ, et al. 2011. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol. Cancer 10:10
178. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. 1995. Signalling downstream of activated mammalian Notch. Nature 377:355-58
179. Whelan JT, Forbes SL, Bertrand FE. 2007. CBF-1 (RBP-J?) binds to the PTEN promoter and regulates PTEN gene expression. Cell Cycle 6:80-84
180. Whelan JT, Kellogg A, Shewchuk BM, Hewan-Lowe K, Bertrand FE. 2009. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. J. Cell. Biochem. 107:992-1001
181. Hettinger K, Vikhanskaya F, Poh MK, Lee MK, deBelle I, et al. 2007. c-Jun promotes cellular survival by suppression of PTEN. Cell Death Differ. 14:218-29
182. Tamguney T, Stokoe D. 2007. New insights into PTEN. J. Cell Sci. 120:4071-79
183. Guo H, Ingolia NT, Weissman JS, Bartel DP. 2010. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466:835-40
184. Jin HY, Oda H, Lai M, Skalsky RL, Bethel K, et al. 2013. MicroRNA-17?92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J. 32:2377-91
185. Hong L, Lai M, Chen M, Xie C, Liao R, et al. 2010. The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence. Cancer Res. 70:8547-57
186. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, et al. 2009. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 23:2839-49
187. Lujambio A, Lowe SW. 2012. The microcosmos of cancer. Nature 482:347-55
188. Cai J, Fang L, Huang Y, Li R, Yuan J, et al. 2013. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res. 73:5402-15
189. Johnsson P, Ackley A, Vidarsdottir L, Lui WO, CorcoranM, et al. 2013. A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells. Nat. Struct. Mol. Biol. 20:440-46
190. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. 2010. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465:1033-38
191. Pei B, Sisu C, Frankish A, Howald C, Habegger L, et al. 2012. The GENCODE pseudogene resource. Genome Biol. 13:R51
192. Poliseno L. 2012. Pseudogenes: newly discovered players in human cancer. Sci. Signal. 5:re5
193. Alvarez-Nun∼ez F, Bussaglia E, Mauricio D, Ybarra J, Vilar M, et al. 2006. PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 16:17-23
194. Garc JM, Silva J, Pen∼a C, Garcia V, Rodr?́uez R, et al. 2004. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 41:117-24
195. Ho CM, Lin MC,Huang SH,Huang CJ, Lai HC, et al. 2009. PTEN promotermethylation andLOHof 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. Gynecol. Oncol. 112:307-13
196. Mueller S, Phillips J, Onar-Thomas A, Romero E, Zheng S, et al. 2012. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro-Oncology 14:1146-52
197. Sadeq V, Isar N, Manoochehr T. 2011. Association of sporadic breast cancer with PTEN/MMAC1/ TEP1 promoter hypermethylation. Med. Oncol. 28:420-23
198. Wang L, Wang WL, Zhang Y, Guo SP, Zhang J, Li QL. 2007. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol. Res. 37:389-96
199. Hollander MC, Blumenthal GM, Dennis PA. 2011. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 11:289-301
200. Bennett KL,Mester J,Eng C. 2010. Germline epigenetic regulation ofKILLIN inCowden and Cowdenlike syndrome. J. Am. Med. Assoc. 304:2724-31
201. Cho YJ, Liang P. 2008. Killin is a p53-regulated nuclear inhibitor of DNA synthesis. Proc. Natl. Acad. Sci. USA 105:5396-401
202. Thompson ER, Gorringe KL, Choong DY, Eccles DM, Mitchell G, Campbell IG. 2012. Analysis of KLLN as a high-penetrance breast cancer predisposition gene. Breast Cancer Res. Treat. 134:543-47
203. Bennett KL, Campbell R, Ganapathi S, Zhou M, Rini B, et al. 2011. Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma. Genes Chromosomes Cancer 50:654-61
204. Zhou J, Parada LF. 2012.PTENsignaling in autism spectrum disorders. Curr. Opin.Neurobiol. 22:873-79
205. Chalhoub N, Baker SJ. 2009. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol.Mech. Dis. 4:127-50
206. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, et al. 2003. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1:E59
207. Carracedo A, Alimonti A, Pandolfi PP. 2011. PTEN level in tumor suppression:How much is too little? Cancer Res. 71:629-33